Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Singular Health GroupASX:SHG 27 3-Year EBITDA Growth Rate is 22.60% as of Dec. 2025, which is 0% below its 10-year median of 22.65. GuruFocus rates ASX:SHG with a GF Score™ of 27/100 and a GF Value™ of A$0.11 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Singular Health Group ranks better than 69.01% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Singular Health Group was 22.70% per year. The lowest was 22.60% per year. And the median was 22.65% per year.
Singular Health Group (ASX:SHG) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Singular Health Group 3-Year EBITDA Growth Rate Related Terms
ASX:SHG vs VEEV, BTSG, HQY: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Singular Health Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Singular Health Group 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Singular Health Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Singular Health Group's 3-Year EBITDA Growth Rate falls into.
Singular Health Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.60% mean?
Singular Health Group (ASX:SHG) has a 3-Year EBITDA Growth Rate of 22.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Singular Health Group and its competitors. This is near median its historical median of 22.65. Over the past decade, Singular Health Group's 3-Year EBITDA Growth Rate has ranged from 22.60 to 22.70. According to the industry distribution chart, Singular Health Group ranks #163 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 31%.
Is Singular Health Group's 3-Year EBITDA Growth Rate too high?
Singular Health Group's current 3-Year EBITDA Growth Rate of 22.60% is near median its 10-year median of 22.65. Over the past 10 years, this metric has ranged from a low of 22.60 to a high of 22.70. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Singular Health Group's value of 22.60% is 121.6% above this industry median. Based on the distribution chart, Singular Health Group ranks #163 out of 526 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Singular Health Group has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Singular Health Group's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Singular Health Group ranks #163 out of 526 companies for 3-Year EBITDA Growth Rate. This puts Singular Health Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Singular Health Group's value of 22.60% is 121.6% above this benchmark. Historically, Singular Health Group's own 3-Year EBITDA Growth Rate has ranged from 22.60 to 22.70 over the past decade. While the company's 10-year median is 22.65 vs. the industry median of 10.20, Singular Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Singular Health Group's current 3-Year EBITDA Growth Rate of 22.60% is 121.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Singular Health Group and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Singular Health Group's current 3-Year EBITDA Growth Rate is 22.60%, which is near median its own 10-year median of 22.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Singular Health Group stock overvalued right now?
Based on GuruFocus' analysis, Singular Health Group (ASX:SHG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.11, compared to a current price of A$0.19 — trading 72.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 22.60%, which is near median its 10-year median of 22.65 and 121.6% above the Healthcare Providers & Services industry median of 10.20. Singular Health Group's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Singular Health Group (ASX:SHG), the current 3-Year EBITDA Growth Rate is 22.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Singular Health Group (ASX:SHG) Overvalued in 2026?
Based on GuruFocus' analysis, Singular Health Group stock appears to be overvalued.
The current stock price of A$0.19 is trading 72.7% above its estimated GF Value™ of A$0.11.
GuruFocus considers Singular Health Group to be Significantly Overvalued.
Key valuation signals for ASX:SHG:
3-Year EBITDA Growth Rate: 22.60% (near median its 10-year median of 22.65)
GF Value™: A$0.11 vs. price of A$0.19 (72.7% above fair value)
Industry Position: 121.6% above the Healthcare Providers & Services median (#163 of 526)
No single metric tells the full story. See the ASX:SHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Singular Health Group Ltd provides medical software solutions. The company's business segment is the provision of Volume Rendering Platform (VRP) software, providing 3D printing services and 3D machine sales. It operates in one segment, which is the provision and development of medical technology within Australia.
27GF Score
Get the complete analysis for ASX:SHG
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SHG has been successfully added to your 
